Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function after Ischemic and Nonischemic Injury in the Mouse

Journal of Cardiovascular Pharmacology

Volumn 66, Issue 1, 2015, Pages 1-8

  Marchetti, Carlo ^a,b,c   Toldo, Stefano ^a,b   Chojnacki, Jeremy ^d   Mezzaroma, Eleonora ^e   Liu, Kai ^d   Salloum, Fadi N ^a   Nordio, Andrea ^a,b   Carbone, Salvatore ^a,b   Mauro, Adolfo Gabriele ^a,b   Das, Anindita ^a   Zalavadia, Ankit A ^a   Halquist, Matthew S ^a   Federici, Massimo ^c   Van Tassell, Benjamin W ^a,b,e   Zhang, Shijun ^d   Abbate, Antonio ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Victoria Johnson Research Laboratories   (United States)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d Hunter Holmes McGuire Vet Aff MC   (United States)

^e Pharmacotherapy and Outcome Sciences   (United States)

Author keywords

acute myocardial infarction; caspase 1; inflammasome; inflammation; NLRP3

Indexed keywords

CARDIOVASCULAR AGENT; CRYOPYRIN; DOXORUBICIN; NLRP3 INFLAMMASOME INHIBITOR; PROTEIN INHIBITOR; TROPONIN I; UNCLASSIFIED DRUG; CARRIER PROTEIN; NLRP3 PROTEIN, MOUSE;

ACUTE HEART INFARCTION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CELL DEATH; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOPPLER ECHOCARDIOGRAPHY; EXPERIMENTAL MODEL; HEART FUNCTION; HEART INFARCTION SIZE; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; LEFT CORONARY ARTERY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPERFUSION INJURY; SYSTOLIC DYSFUNCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY;

ANIMALS; CARRIER PROTEINS; DOXORUBICIN; MALE; MICE; MICE, INBRED ICR; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN;

EID: 84937702457     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000247     Document Type: Article

References (38)

1. Strowig T, Henao-Mejia J, Elinav E, et al. Inflammasomes in health and disease. Nature. 2012;481:278-286.
2. Franchi L, Eigenbrod T, Munoz-Planillo R, et al. The inflammasome: a caspase-1-Activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009;10:241-247.
3. Stutz A, Golenbock DT, Latz E. Inflammasomes: too big to miss. J Clin Invest. 2009;119:3502-3511.
4. Mezzaroma E, Toldo S, Farkas D, et al. The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proc Natl Acad Sci U S A. 2011;108:19725-19730.
5. Kawaguchi M, Takahashi M, Hata T, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123:594-604.
6. Van Tassell BW, Toldo S, Mezzaroma E, et al. Targeting interleukin-1 in heart disease. Circulation. 2013;128:1910-1923.
7. Seropian IM, Toldo S, Van Tassell BW, et al. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol. 2014;63:1593-1603.
8. Lotrionte M, Biondi-Zoccai G, Abbate A, et al. Review and metaanalysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112:1980-1984.
9. Toldo S, Goehe RW, Lotrionte M, et al. Comparative cardiac toxicity of anthracyclines in vitro and in vivo in the mouse. PLoS One. 2013;8: e58421.
10. Sauter KA, Wood LJ, Wong J, et al. Doxorubicin and daunorubicin induce processing and release of interleukin-1beta through activation of the NLRP3 inflammasome. Cancer Biol Ther. 2011;11:1008-1016.
11. Marchetti C, Chojnacki J, Toldo S, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemiareperfusion in the mouse. J Cardiovasc Pharmacol. 2014;63:316-322.
12. Abbate A, Salloum FN, Vecile E, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction. Circulation. 2008;117:2670-2683.
13. Brydges SD, Mueller JL, McGeough MD, et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity. 2009;30:875-887.
14. Go AS, Mozaffarian D, Roger VL, et al. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation. 2014;129:399-410.
15. McMurray JJ, Petrie MC, Murdoch DR, et al. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19 (suppl l):P9-P16.
16. Miller TD, Christian TF, Hopfenspirger MR, et al. Infarct size after acute myocardial infarction measured by quantitative tomographic 99mTc sestamibi imaging predicts subsequent mortality. Circulation. 1995;92: 334-341.
17. Sanz G, Castaner A, Betriu A, et al. Determinants of prognosis in survivors of myocardial infarction: a prospective clinical angiographic study. N Engl J Med. 1982;306:1065-1070.
18. Abbate A, Kontos MC, Biondi-Zoccai GG. No-reflow: the next challenge in treatment of ST-elevation acute myocardial infarction. Eur Heart J. 2008;29:1795-1797.
19. Abbate A, Van Tassell BW, Seropian IM, et al. Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse. Eur J Heart Fail. 2010;12:319-322.
20. Van Tassell BW, Varma A, Salloum FN, et al. Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice. J Cardiovasc Pharmacol. 2010;55:117-122.
21. Toldo S, Mezzaroma E, Van Tassell BW, et al. Interleukin-1beta blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse. Exp Physiol. 2013;98: 734-745.
22. Toldo S, Mezzaroma E, Bressi E, et al. Interleukin-1beta blockade improves left ventricular systolic/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse. J Cardiovasc Pharmacol. 2014;64:1-6.
23. Abbate A, Kontos MC, Grizzard JD, et al, VCU-ART Investigators. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). Am J Cardiol. 2010;105:1371-1377.e1.
24. Abbate A, Van Tassell BW, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCUART2) pilot study. Am J Cardiol. 2013;111:1394-1400.
25. Abbate A, Kontos MC, Abouzaki NA, et al. Comparative safety of Interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCUART2 pilot studies). Am J Cardiol. 2015;115:288-292.
26. Sandanger O, Ranheim T, Vinge LE, et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemiareperfusion injury. Cardiovasc Res. 2013;99:164-174.
27. Liu Y, Lian K, Zhang L, et al. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. Basic Res Cardiol. 2014;109:415-014-0415-z.
28. Zhu J, Zhang J, Zhang L, et al. Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity. Biomed Pharmacother. 2011;65: 481-485.
29. Bracey NA, Beck PL, Muruve DA, et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta. Exp Physiol. 2013;98:462-472.
30. Abbate A. The heart on fire: inflammasome and cardiomyopathy. Exp Physiol. 2013;98:385.
31. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11:633-652.
32. Toldo S, Seropian IM, Mezzaroma E, et al. Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. J Mol Cell Cardiol. 2011;51:244-251.
33. Toldo S, Das A, Mezzaroma E, et al. Induction of microRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice. Circ Cardiovasc Genet. 2014;7:311-320.
34. Dobaczewski M, de Haan JJ, Frangogiannis NG. The extracellular matrix modulates fibroblast phenotype and function in the infarcted myocardium. J Cardiovasc Transl Res. 2012;5:837-847.
35. Van Tassell BW, Seropian IM, Toldo S, et al. Interleukin-1beta induces a reversible cardiomyopathy in the mouse. Inflamm Res. 2013;62:637-640.
36. Van Tassell BW, Arena RA, Toldo S, et al. Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure. PLoS One. 2012;7:e33438.
37. Toldo S, Mezzaroma E, O'Brien L, et al. Interleukin-18 mediates interleukin-1-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol. 2014;306:H1025-H1031.
38. O'brien LC, Mezzaroma E, Van Tassell BW, et al. Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure. Mol Med. 2014;20:221-229.